The annual European Crohn’s and Colitis Organisation (ECCO) Congress is the biggest event in the inflammatory bowel disease calendar. The ECCO'22 scientific programme includes a wide range of sessions presented by some of the world’s top specialists, exploring basic science, traditional medicine and clinical practice, as well as a wealth of exciting new data!
Galapagos is excited to be a sponsor at ECCO'22 and to be delivering an interactive live symposium, as well as a range of other exciting activities throughout the congress. We look forward to meeting you at ECCO'22!
Through discursive talks, this session will explore multidisciplinary perspectives on managing patient burden in UC, examine the importance of alignment between patient and healthcare professional treatment goals as part of HAPPI-R, and explore the key data and practical considerations for use of the preferential JAK1 inhibitor filgotinib as a new treatment option for moderately-to-severely active UC. Following three interactive presentations from our speakers, as well as several special guests, the session will end with a live discussion and Q+A. Make sure to join us in Strauss rooms 1+2 at 18:45 CET for a chance to gain insights and experience directly from the experts and ask them your questions!
This programme is not affiliated with ECCO
Professor Iris Dotan (Chair)
Director, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel
Prof. Iris Dotan’s research interests lie in biomarker-based stratification of patients with IBD, personalised treatment and care, biologics, and novel therapies. Her translational research explores mucosal immunology, focussing on the interactions of intestinal epithelial cells and mucosal lymphocytes with their environment. She is Past President of the Israeli Association of Gastroenterology and Liver Diseases, Vice Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), a member of ECCO and the Scientific Committee of UEG, and the founder of the Israeli IBD Research Nucleus.
Professor Séverine Vermeire
Professor of Medicine, Universitair Ziekenhuis Leuven, Belgium
Prof. Séverine Vermeire obtained her MD and PhD at KU Leuven and has also trained at the National University of Asuncion, Paraguay, the Wellcome Centre for Human Genetics, UK, and Montreal General Hospital, Canada. Since 2003, she has been a staff member at the Gastroenterology Department of University Hospitals Leuven and is Professor of Medicine at KU Leuven, becoming Head of the Department of Chronic Diseases and Metabolism in 2016. Prof. Vermeire has been a principal investigator in several randomised controlled trials with new therapeutic compounds. Her work, which focuses on the role of the microbiome, genetic susceptibility in IBD and signatures predictive of therapy response, has led to over 500 peer-reviewed articles.
Professor Gionata Fiorino, MD, PhD
Senior gastroenterologist and clinical researcher, Department of Gastroenterology and Digestive Endoscopy, San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
Prof. Gionata Fiorino completed his medical degree in 2004, specialised in gastroenterology in 2009 and obtained his PhD in 2013. His research focusses on early diagnosis, non-invasive monitoring, imaging techniques, novel therapies and biosimilars, and quality of care in IBD. He has collaborated on over 230 peer-reviewed articles and has recently coordinated the first GRADE-based ECCO Guidelines on Therapeutics in Crohn’s Disease and the first ECCO Consensus on Quality of Care Standards in IBD. He is currently Chair of the Scientific Committee of the Italian Group for the study of IBD and Associate Editor of the Journal of Crohn’s and Colitis.